These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30904418)

  • 1. [Treatment of patients with brain metastases from a melanoma].
    Modesto A; Chira C; Sol JC; Lubrano V; Boulinguez S; Pagès C; Sibaud V; Gomez-Roca C; Moyal É; Meyer N
    Cancer Radiother; 2019 Apr; 23(2):147-150. PubMed ID: 30904418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Systemic treatment of melanoma brain metastases].
    Le Rhun É; Mateus C; Mortier L; Dhermain F; Guillot B; Grob JJ; Lebbe C; Thomas M; Jouary T; Leccia MT; Robert C
    Cancer Radiother; 2015 Feb; 19(1):48-54. PubMed ID: 25656856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
    Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
    Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
    Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Effectiveness of Immunoradiotherapy on Brain-metastatic BRAF/MEK Inhibitor-resistant Melanoma with Balloon Cell Change.
    Goto H; Shimauchi T; Fukuchi K; Yokota N; Koizumi S; Aoshima M; Endo Y; Masuda Y; Miyazawa H; Kasuya A; Nakamura K; Ito T; Tokura Y
    Acta Derm Venereol; 2019 May; 99(6):612-613. PubMed ID: 30673109
    [No Abstract]   [Full Text] [Related]  

  • 6. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Therapies for Advanced Melanoma.
    Bomar L; Senithilnathan A; Ahn C
    Dermatol Clin; 2019 Oct; 37(4):409-423. PubMed ID: 31466582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
    Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
    J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control.
    Alvarez-Breckenridge C; Giobbie-Hurder A; Gill CM; Bertalan M; Stocking J; Kaplan A; Nayyar N; Lawrence DP; Flaherty KT; Shih HA; Oh K; Batchelor TT; Cahill DP; Sullivan R; Brastianos PK
    Oncologist; 2019 May; 24(5):671-679. PubMed ID: 30796152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Metastatic Melanoma in 2018.
    Kaufman HL; Margolin K; Sullivan R
    JAMA Oncol; 2018 Jun; 4(6):857-858. PubMed ID: 29621376
    [No Abstract]   [Full Text] [Related]  

  • 11. Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases.
    Cabanie C; Biau J; Durando X; Mansard S; Molnar I; Chassin V; Verrelle P; Khalil T; Lapeyre M; Dupic G
    Cancer Radiother; 2021 Jul; 25(5):432-440. PubMed ID: 33836954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.
    Ly D; Bagshaw HP; Anker CJ; Tward JD; Grossmann KF; Jensen RL; Shrieve DC
    J Neurosurg; 2015 Aug; 123(2):395-401. PubMed ID: 25768829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases.
    Grätz V; Langan EA; Neumann A; Zillikens D; Terheyden P
    Melanoma Res; 2019 Oct; 29(5):516-521. PubMed ID: 30870272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
    Di Giacomo AM; Margolin K
    Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases.
    Patel BG; Ahmed KA; Johnstone PA; Yu HH; Etame AB
    Melanoma Res; 2016 Aug; 26(4):382-6. PubMed ID: 26926151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy.
    Shi DD; Arnaout O; Bi WL; Buchbinder EI; Cagney DN; Insco ML; Liu D; Schoenfeld JD; Aizer AA
    World Neurosurg; 2020 Jul; 139():226-231. PubMed ID: 32330622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study.
    Gatterbauer B; Hirschmann D; Eberherr N; Untersteiner H; Cho A; Shaltout A; Göbl P; Fitschek F; Dorfer C; Wolfsberger S; Kasprian G; Höller C; Frischer JM
    Cancer Med; 2020 Jun; 9(11):4026-4036. PubMed ID: 32249551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.
    Wolf A; Zia S; Verma R; Pavlick A; Wilson M; Golfinos JG; Silverman JS; Kondziolka D
    J Neurooncol; 2016 May; 127(3):607-15. PubMed ID: 26852222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma brain metastasis: overview of current management and emerging targeted therapies.
    Fonkem E; Uhlmann EJ; Floyd SR; Mahadevan A; Kasper E; Eton O; Wong ET
    Expert Rev Neurother; 2012 Oct; 12(10):1207-15. PubMed ID: 23082737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.